GGHC
MAZE

Gilder Gagnon Howe & Co’s Maze Therapeutics MAZE Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,487
Closed -$522K – 299
2026
Q1 		$522K Sell
17,487
-5,795
-25% -$256K 0.01% 233
2025
Q4 		$965K Buy
+23,282
New +$800K 0.01% 219

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Gilder Gagnon Howe & Co's MAZE Position: Q2 2026 in Review

Gilder Gagnon Howe & Co sold out of Maze Therapeutics (MAZE) in Q2 2026, closing a stake of 17,487 shares — an estimated $522K sold.

Gilder Gagnon Howe & Co first reported a position in MAZE in Q4 2025 and held it in 2 quarters. The position peaked at $965K in Q4 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Gilder Gagnon Howe & Co reported no remaining Maze Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 17,487 Maze Therapeutics shares in Q2 2026, an estimated $522K.
  • Gilder Gagnon Howe & Co first reported a position in Maze Therapeutics in Q4 2025 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's Maze Therapeutics position peaked at $965K in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2026, filed 14 Aug 2026.